...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs and aging >Pravastatin: a review of its use in elderly patients.
【24h】

Pravastatin: a review of its use in elderly patients.

机译：普伐他汀：审查其在老年患者中的使用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pravastatin (Pravachol) is a competitive, reversible HMG-CoA reductase inhibitor that lowers serum cholesterol levels by inhibiting de novo cholesterol synthesis and has antiatherogenic effects that appear to be partially independent of its lipid-lowering effects.Pravastatin 10-40 mg/day produced significant reductions (vs baseline or placebo) in serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels in elderly patients (aged >or=60 or >or= 65 years) with hypercholesterolaemia or normal cholesterol levels. Serum triglyceride and high-density lipoprotein cholesterol levels also improved in some studies, but not in others. Coadministration of cholestyramine, another lipid-lowering agent, further enhanced the lipid-lowering effects of pravastatin in elderly patients. Data from the large, long-term (3-6 years) PROspective Study Of Pravastatin in the Elderly at Risk (PROSPER), Cholesterol And Recurrent Events trial (CARE) and Long term Intervention with Pravastatin in Ischaemic Disease (LIPID) trials demonstrated that pravastatin 40 mg/day reduces coronary events in elderly patients with hypercholesterolaemia or normal cholesterol levels, with or at high risk of developing coronary heart disease (CHD). In these trials, the incidence of death from CHD or the combined endpoint of death from CHD or nonfatal myocardial infarction was significantly lower in pravastatin than in placebo recipients.Pravastatin is well tolerated in the elderly, and adverse effects considered related to therapy are minimal. The most commonly occurring adverse events included gastrointestinal events, renal or genital system events, respiratory disorders, headaches and musculoskeletal pain. CONCLUSION: Pravastatin effectively lowers serum TC and LDL-C levels and, as demonstrated in major clinical outcome trials, reduces coronary events in elderly patients with hypercholesterolaemia or normal cholesterol levels. Pravastatin is well tolerated and as such should be considered a first-line agents for primary or secondary prevention in older individuals with evident CHD or multiple risk factors for CHD.
机译：普伐他汀（Pravachol）是一种竞争性可逆的HMG-CoA还原酶抑制剂，可通过抑制从头胆固醇合成来降低血清胆固醇水平，并具有抗动脉粥样硬化作用，似乎部分独立于其降脂作用。普伐他汀10-40 mg / day高胆固醇血症或正常胆固醇水平的老年患者（年龄≥60岁或≥65岁）的血清总胆固醇（TC）和低密度脂蛋白胆固醇（LDL-C）水平显着降低（与基线或安慰剂相比）。在一些研究中，血清甘油三酸酯和高密度脂蛋白胆固醇水平也有所改善，但在其他研究中则没有。与另一种降脂药消胆胺合用可进一步增强普伐他汀对老年患者的降脂作用。普伐他汀在高危老年人中的长期，长期（3-6岁）前瞻性研究（PROSPER），胆固醇和复发事件试验（CARE）的数据以及普伐他汀在缺血性疾病中的长期干预（LIPID）试验的数据表明，普伐他汀40 mg / day可以减少患有高胆固醇血症或胆固醇水平正常，患有冠心病（CHD）或处于冠心病（CHD）高危的老年患者的冠状动脉事件。在这些试验中，普伐他汀比安慰剂接受者的冠心病死亡或冠心病或非致命性心肌梗死合并终点的发生率显着更低，老年人对普伐他汀的耐受性良好，与治疗相关的不良反应极小。最常见的不良事件包括胃肠道事件，肾或生殖系统事件，呼吸系统疾病，头痛和肌肉骨骼疼痛。结论：普伐他汀可有效降低血清TC和LDL-C水平，并且如主要临床结果试验所示，可降低高胆固醇血症或正常胆固醇水平的老年患者的冠状动脉事件。普伐他汀耐受性良好，因此应被视为具有明显冠心病或冠心病危险因素的老年个体一线或二级预防的一线药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号